This study tests a new drug, **ANO31905**, combined with chemotherapy, for treating a type of pancreatic cancer that can't be removed by surgery or has spread to other parts of the body. The focus is on cancer that has a protein called **CLDN18.2**. The study checks if the drug combo is safe and works well.

**Eligibility:** Adults 18+ with a special type of pancreatic cancer can join. They need a good health score (ECOG 0-1), and cancer must have a specific protein (CLDN18.2). Women must not be pregnant. Some people can't join, like those who had other cancers recently or have certain health problems.

• **Study Length:** Participants need to be available for several months.
• **Visits Needed:** Frequent visits to the study site are required.
• **Risks:** Standard chemotherapy side effects plus potential unknown risks from the new drug.

This study offers a chance to try a new treatment, but it's important to consider the commitment and potential risks.